Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027

Mountain View, CA, 22 Oct, 2026 - (ACN Newswire via SeaPRwire.com) - Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug…